

# 1 SARS-CoV-2 antigens expressed in plants detect antibody responses in 2 COVID-19 patients

3

4 Mohau S. Makatsa<sup>1,2†</sup>, Marius B. Tincho<sup>1,2†</sup>, Jerome M. Wendoh<sup>1,2†</sup>, Sherazaan D. Ismail<sup>1,2</sup>,  
5 Rofhiwa Nesamari<sup>1,2</sup>, Francisco Pera<sup>3</sup>, Scott de Beer<sup>3</sup>, Anura David<sup>4</sup>, Sarika Jugwanth<sup>5</sup>,  
6 Maemu P. Gededzha<sup>5</sup>, Nakampe Mampeule<sup>5</sup>, Ian Sanne<sup>6</sup>, Wendy Stevens<sup>4</sup>, Lesley Scott<sup>4</sup>,  
7 Jonathan Blackburn<sup>1,7</sup>, Elizabeth S. Mayne<sup>5</sup>, Roanne S. Keeton<sup>1,2</sup>, Wendy A. Burgers<sup>1,2,8\*</sup>

8

9 <sup>1</sup>Institute of Infectious Disease and Molecular Medicine, and <sup>2</sup>Division of Medical Virology,  
10 Department of Pathology, University of Cape Town, Cape Town, South Africa; <sup>3</sup>Cape Bio  
11 Pharms, Cape Town, South Africa; <sup>4</sup>Department of Molecular Medicine and Haematology,  
12 University of Witwatersrand, Johannesburg, South Africa; <sup>5</sup>Department of Immunology,  
13 Faculty of Health Sciences, University of Witwatersrand and National Health Laboratory  
14 Service Johannesburg, South Africa; <sup>6</sup>Clinical HIV Research Unit, Department of Internal  
15 Medicine, University of Witwatersrand, Johannesburg, South Africa; <sup>7</sup>Division of Chemical  
16 and Systems Biology, Department of Integrative Biomedical Sciences, University of Cape  
17 Town, Cape Town, South Africa; <sup>8</sup>Wellcome Centre for Infectious Diseases Research in  
18 Africa, University of Cape Town, Cape Town, South Africa.

19

20 **\*Corresponding author:** Wendy Burgers, Institute of Infectious Disease and Molecular  
21 Medicine, Faculty of Health Sciences, University of Cape Town, Observatory 7925, South  
22 Africa; Phone: +27-21-4066090; ([wendy.burgers@uct.ac.za](mailto:wendy.burgers@uct.ac.za)).

23

24 <sup>†</sup>M.S.M., M.B.T. and J.M.W. contributed equally to this work.

25

## 26 Manuscript information:

27 Running title: SARS-CoV-2 ELISA using plant-produced proteins

28 Abstract: 341 words; Manuscript word count: 4522; Figures: 6, Tables: 1

29 Keywords: SARS-CoV-2, COVID-19, serology, ELISA, plant expression

30

31 **Funding:** This work was supported by the Wellcome Centre for Infectious Diseases Research  
32 in Africa (CIDRI-Africa), which is supported by core funding from the Wellcome Trust  
33 [203135/Z/16/Z]. Sample collection was funded through the EQUIP grant AID-OAA-A-15-  
34 00070- Antiretroviral Therapy Simplification-Optimization of Programs and Services (ART-  
35 OPS) COVID supplement and through iLEAD BMGF (i-LEAD) grant ID OPP1171455. The  
36 funders had no role in study design, data collection and analysis, decision to publish, or  
37 preparation of the manuscript. The views expressed are those of the authors, and the funders  
38 are not responsible for any use that may be made of the information contained herein.

39

40 **Declaration of interests:** Francisco Pera and Scott de Beer are employed by Cape Bio Pharms.  
41 The remaining authors declare that the research was conducted in the absence of any  
42 commercial or financial relationships that could be construed as a potential conflict of interest.

43

44 **Acknowledgements:** We thank Tamlyn Shaw of Cape Bio Pharms. We also thank Markus  
45 Sack from Pro-SPR GmbH, Alsdorf, Germany for his assistance in designing the S1 and RBD  
46 genes. We thank Muneerah Smith for inactivation and aliquoting of samples. We thank the  
47 study participants for providing samples. We are immensely grateful to Florian Krammer and  
48 his laboratory at Icahn School of Medicine at Mount Sinai, USA, for rapidly sharing their  
49 reagents, protocols and results with the scientific community, and being a model of what our  
50 science should be openly accessible and in the service of humankind.

51

52 **Author contributions:** Conceived and designed the study and experiments: WAB, MSM,  
53 MBT, JMW, FP, SdB, ESM, LS and JB. Provided support and critical protocol review: WS,  
54 IS. Performed the experiments: MSM, MBT, JMW, AD, SJ, NM, MG, FP, SdB. Analyzed the  
55 data: MSM, AD, SJ, NM, MG, SDI, RN, RSK and WAB. Wrote the paper: FP, SDI, RN, RSK,  
56 MBT, JMW, MSM and WAB. All authors approved the final manuscript.

57

## 58 **Contribution to the Field Statement**

59 The SARS-CoV-2 pandemic poses a significant global threat to lives and livelihoods, with over  
60 16 million confirmed cases and at least 650 000 deaths from COVID-19 in the first 7 months  
61 of the pandemic. Developing tools to measure antibody responses and understand protective  
62 immunity to SARS-CoV-2 is a priority. Many expression systems exist to produce the proteins  
63 required in the establishment of these serological assays, but plant-based systems have several  
64 advantages over more widely used conventional protein expression systems. Most notably, they  
65 are rapid, scaleable and cost-effective, making them attractive protein expression systems  
66 particularly in low-income settings such as ours in Africa. We were able to develop a cost-  
67 effective serological assay by making use of plant-produced viral antigens. Our study  
68 demonstrates that recombinant SARS-CoV-2 proteins produced in plants enable the robust  
69 detection of SARS-CoV-2-specific antibodies equivalent to that observed in a high sensitivity  
70 commercial assay in which antigens were produced in a mammalian expression system. Our  
71 ELISA can be used to evaluate SARS-CoV-2 seroprevalence, describe the kinetics of the  
72 humoral immune response in infected individuals, and investigate humoral immunity in our  
73 setting where comorbidities are highly prevalent.

## 74 Abstract

75 **Background:** The SARS-CoV-2 pandemic has swept the world and poses a significant global  
76 threat to lives and livelihoods, with over 16 million confirmed cases and at least 650 000 deaths  
77 from COVID-19 in the first 7 months of the pandemic. Developing tools to measure  
78 seroprevalence and understand protective immunity to SARS-CoV-2 is a priority. We aimed  
79 to develop a serological assay using plant-derived recombinant viral proteins, which represent  
80 important tools in less-resourced settings.

81  
82 **Methods:** We established an indirect enzyme-linked immunosorbent assay (ELISA) using the  
83 S1 and receptor-binding domain (RBD) portions of the spike protein from SARS-CoV-2,  
84 expressed in *Nicotiana benthamiana*. We measured antibody responses in sera from South  
85 African patients (n=77) who had tested positive by PCR for SARS-CoV-2. Samples were taken  
86 a median of six weeks after the diagnosis, and the majority of participants had mild and  
87 moderate COVID-19 disease. In addition, we tested the reactivity of pre-pandemic plasma  
88 (n=58) and compared the performance of our in-house ELISA with a commercial assay. We  
89 also determined whether our assay could detect SARS-CoV-2-specific IgG and IgA in saliva.

90  
91 **Results:** We demonstrate that SARS-CoV-2-specific immunoglobulins are readily detectable  
92 using recombinant plant-derived viral proteins, in patients who tested positive for SARS-CoV-  
93 2 by PCR. Reactivity to S1 and RBD was detected in 51 (66%) and 48 (62%) of participants,  
94 respectively. Notably, we detected 100% of samples identified as having S1-specific antibodies  
95 by a validated, high sensitivity commercial ELISA, and OD values were strongly and  
96 significantly correlated between the two assays. For the pre-pandemic plasma, 1/58 (1.7%) of  
97 samples were positive, indicating a high specificity for SARS-CoV-2 in our ELISA. SARS-  
98 CoV-2-specific IgG correlated significantly with IgA and IgM responses. Endpoint titers of  
99 S1- and RBD-specific immunoglobulins ranged from 1:50 to 1:3200. S1-specific IgG and IgA  
100 were found in saliva samples from convalescent volunteers.

101  
102 **Conclusions:** We demonstrate that recombinant SARS-CoV-2 proteins produced in plants  
103 enable robust detection of SARS-CoV-2 humoral responses. This assay can be used for  
104 seroepidemiological studies and to measure the strength and durability of antibody responses  
105 to SARS-CoV-2 in infected patients in our setting.

## 106 Introduction

107 The current global pandemic, caused by the novel severe acute respiratory syndrome  
108 coronavirus 2 (SARS-CoV-2), has resulted in over 16 million cases and at least 650 000 deaths,  
109 as of 27 July 2020. SARS-CoV-2 was first detected in December 2019 in Wuhan, a city in the  
110 Hubei province of China, and is thought to originate from zoonotic transmission of a bat  
111 coronavirus (Tan et al., 2020; Zhu et al., 2020). Coronavirus disease 2019 (COVID-19), the  
112 resultant disease, is commonly associated with fever, cough and fatigue, and in severe cases,  
113 pneumonia and respiratory failure (Chan et al., 2020).

114 SARS-CoV-2 is a 30kB positive-stranded RNA virus that is a member of the  
115 *Betacoronavirus* genus and the subgenus *Sarbecovirus* (Letko et al., 2020). The genus harbours  
116 human pathogens that cause respiratory infections, namely the highly virulent SARS-CoV and  
117 Middle East respiratory syndrome coronavirus (MERS-CoV), as well as the circulating  
118 ‘common cold’ human coronavirus (hCoV)-OC43 and hCoV-HKU1 (Su et al., 2016).  
119 Betacoronaviruses express four essential structural proteins, namely the spike (S) glycoprotein,  
120 membrane (M) protein, envelope (E) protein and nucleocapsid (N) protein, as well as multiple  
121 accessory and non-structural proteins (Neuman et al., 2011, Lu et al., 2020). The S glycoprotein  
122 is a homotrimer that protrudes from the surface of the viral particles (Tortorici and Velesler,  
123 2019), and interacts with the human cell receptor angiotensin converting enzyme 2 (ACE2)  
124 through the receptor-binding domain (RBD), gaining viral entry into the host cell (Li 2016;  
125 Letko et al., 2020; Walls et al., 2020). S is cleaved by host cell proteases into two subunits: the  
126 S1 subunit which harbours the RBD and enables binding to host cell receptors, and the S2  
127 subunit that is important for fusion with the host cell membrane (Walls et al., 2020; Wrapp et  
128 al., 2020).

129 The S1 subunit is highly immunogenic, and its RBD portion is the main target of  
130 neutralizing antibodies, thus becoming the focus of serological studies (Amanat et al., 2020;  
131 Huang et al., 2020; Liu et al., 2020; Okba et al., 2020). Recently, potent neutralizing antibodies  
132 isolated from the convalescent sera of SARS-CoV-2 patients were demonstrated to be  
133 protective against disease from high-dose SARS-CoV-2 challenge in a small animal model  
134 (Rogers et al., 2020), suggesting the potential for therapeutic interventions as well as inferring  
135 that recovered SARS-CoV-2 patients may be afforded protection from re-infection by  
136 neutralizing antibody responses. Amanat et al (2020) showed a strong correlation between the  
137 neutralizing antibody response and ELISA endpoint titers against S, suggesting the use of  
138 serological assays in estimating the percentage of infected people who have neutralizing  
139 antibodies that protect them from re-infection or disease.

140 Serological assays that can detect antibody responses to SARS-CoV-2 are critical for  
141 answering pressing questions regarding immunity to the virus. It is not known what proportion  
142 of infected individuals elicit antibodies to SARS-CoV-2, if antibodies serve as correlates of  
143 protection, and if so, what the threshold of binding or neutralizing titers are that will provide  
144 immunity, and the duration of these responses. Serological assays such as enzyme-linked  
145 immunosorbent assays (ELISA) can assist in answering these questions. These assays need to  
146 be both sensitive as well as demonstrate high specificity for SARS-CoV-2, and not give false  
147 positives due to cross-reactivity with widely circulating hCoVs NL63, 229E, OC43, and  
148 HKU1. While the N protein is more conserved among coronaviruses, the S protein sequence  
149 has lower sequence conservation. The S1 portion is 21-25% identical at the amino acid level  
150 to circulating hCoVs (Okba et al., 2020). Thus, serological assays using the full-length S  
151 protein, S1 subunit or RBD portion as antigens have shown good specificity with little cross-

152 reactivity to NL63 and 229E (Amanat et al., 2020; Zhao et al., 2020) compared to the use of N  
153 protein (Zhao et al., 2020).

154 Purified recombinant proteins are essential for the establishment of serological assays.  
155 Numerous protein expression systems exist, each with their own advantages and limitations.  
156 These include bacterial, mammalian, yeast, insect and plant-based systems (Shanmugaraj et  
157 al., 2020, Yin et al., 2007). Plant-based systems have several advantages over more widely  
158 used conventional protein expression systems (Shanmugaraj and Ramalingam, 2014). Most  
159 notably, they are rapid, cost-effective and support post-translational modifications similar to  
160 mammalian cell systems, making them attractive protein expression systems particularly in  
161 low-income settings (Shanmugaraj and Ramalingam, 2014 and 2020; Maliga et al., 2004).  
162 Historically, their major disadvantage was low yield (Shanmugaraj et al., 2020), however  
163 advances in plant technology, including transient expression systems and viral vectors, have  
164 led to improvements in protein yield (Kapila et al., 1997; Shanmugaraj and Ramalingam, 2014;  
165 Yamamoto et al., 2018). Additionally, SARS-CoV S1 protein expressed in tomato and tobacco  
166 plants demonstrated good immunogenicity in mice (Pogrebnyak et al., 2005). Together, these  
167 studies highlight the potential of plant-based expression systems for the development of  
168 serological assay reagents as well as vaccines for the current SARS-CoV-2 pandemic.

169 In this study, we describe the development of an ELISA that enables detection of  
170 antibodies directed at the S1 subunit and the RBD portion of the SARS-CoV-2 S glycoprotein,  
171 generated through a plant-based expression system.

172

## 173 **Materials and methods**

### 174 **Recombinant protein cloning and expression**

175 The S1 portion and receptor binding domain (RBD) of the spike protein of SARS-CoV-2  
176 Wuhan-Hu-1 isolate (GenBank: MN908947.3) were produced by Cape Bio Pharms, Cape  
177 Town, South Africa. Briefly, *Nicotiana benthamiana* codon-optimized DNA encoding S1 and  
178 RBD was synthesized commercially (Genscript). Both genes were fused at their C-terminal  
179 region to the fragment crystallizable region (Fc) of rabbit IgG1 (Genbank: L29172.1) and  
180 subsequently cloned into Cape Bio Pharms' proprietary vector, pCBP2. *Agrobacterium*  
181 *tumefaciens* strain GV3101 (pMP90RK) was used to carry agroinfiltration. Growth of  
182 recombinant *A. tumefaciens* and vacuum infiltration of *N. benthamiana* plants was performed  
183 as described previously (Maclean et al., 2007). Three days post-infiltration, leaves were  
184 homogenized in the presence of phosphate buffered saline (PBS) at a 2:1 ratio buffer:leaf  
185 material. Cell debris was removed by centrifugation at 10 000 *g* for 10 min at 4°C, and the  
186 clarified supernatant was used for expression analyses and purification by Protein A affinity  
187 chromatography.

188 For purification, the extract was filtered through a 0.22 µm cellulose nitrate filter  
189 (Sartorius) before loading onto a pre-equilibrated 5 ml column packed with POROS  
190 MabCapture A resin (Thermo Fisher). The column was then washed with 10 column volumes  
191 of wash buffer (PBS, pH 7.5) and bound proteins eluted using elution buffer (0.1 M glycine,  
192 pH 2.5). Eluted fractions were captured in 1/10<sup>th</sup> volume of neutralization buffer (1 M Tris, pH  
193 8.5) and then pooled and applied to a 10K molecular weight cutoff (MWCO) Amicon  
194 centrifuge tube (Millipore) for buffer exchange against PBS and sample concentration. Mouse  
195 anti-rabbit IgG (γ-chain specific) horseradish peroxidase conjugate (1:2500; IgG-HRP, Sigma)



196 was used in a standard SDS-PAGE and western blot analysis to examine purity of the  
197 recombinant proteins.

198

## 199 **Volunteer recruitment and sample collection**

200 Samples were collected from SARS-CoV-2 infected volunteers (n=77) recruited from Gauteng  
201 and the Western Cape provinces of South Africa from 10 April 2020 to 26 May 2020.  
202 Volunteers had previously undergone a reverse transcriptase polymerase chain reaction (RT-  
203 PCR) test for SARS-CoV-2 from an upper respiratory tract (nose/throat) swab collected into  
204 viral transport media. Swabs were processed through approved assays in accredited public and  
205 private clinical laboratories. Inclusion criteria were age  $\geq 18$  years and a confirmed positive  
206 PCR for SARS-CoV-2 on the national database of the National Health Laboratory Services  
207 (NHLS). Of the 77 participants, 34 (44%) had a second positive PCR result recorded within a  
208 week after the first positive test. With respect to disease severity, five participants were  
209 asymptomatic, 23 had mild disease (characterised by mild upper respiratory tract symptoms),  
210 38 had moderate disease (defined by gastrointestinal symptoms or lower respiratory tract  
211 symptoms), and two had severe disease (admission to hospital). Serum and saliva samples were  
212 collected between 8 and 70 days after the first positive PCR test. Ethical approval for these  
213 studies was obtained from the Human Research Ethics Committee (HREC) of the University  
214 of Witwatersrand (M200468) and the University of Cape Town (UCT; 210/2020). All  
215 participants provided written, informed consent.

216 Pre-pandemic plasma (n=58) was obtained from banked human samples that were  
217 collected from participants recruited from Cape Town, South Africa in 2011-2012, from a study  
218 protocol approved by the HREC of the University of Cape Town (158/2010). Storage consent  
219 was provided by all participants, and approval for use of the samples in this study was obtained  
220 from the HREC, UCT. Samples came from participants who were HIV-infected (n=27) or HIV-  
221 uninfected (n=31). All participants had tested positive for exposure to *Mycobacterium*  
222 *tuberculosis* based on a positive IFN- $\gamma$ -release assay (QuantiFERON-TB Gold In-Tube), *i.e.*  
223 were classified as having latent tuberculosis infection. The median age was 26 years  
224 (interquartile range [IQR]: 22-34 years) and 44/58 (76%) were female. All HIV-infected  
225 individuals were antiretroviral treatment (ART)-naive, with a median CD4 count of 591  
226 cells/mm<sup>3</sup> (IQR: 511-749).

227 All samples were treated with 1% Triton-X100 (Sigma) for 60 min at room temperature  
228 to inactivate any potentially live virus in the samples (Remy et al., 2019).

229

## 230 **Enzyme-linked Immunosorbent Assay (ELISA)**

231 The ELISA protocol was adapted from a published protocol (Stadlbauer et al., 2020). Briefly,  
232 96-well plates (Nunc MaxiSorp, Thermo Fisher) were coated at 4°C overnight with 50  $\mu$ l of  
233 varying concentrations (1-4  $\mu$ g/ml) of purified recombinant RBD or S1 proteins in PBS or  
234 bicarbonate buffer (both Sigma). The following day, plates were washed five times using an  
235 automated plate washer and incubated at room temperature in blocking solution (1% casein or  
236 3% non-fat powder milk prepared in PBS with 0.1% Tween 20 (PBS-T)). After 1 h, the  
237 blocking solution was discarded and 100  $\mu$ l of serum, plasma or saliva samples (at 1:50 dilution  
238 for sera/plasma and 1:10 for saliva) were added for 2 h at room temperature. Next, plates were

239 washed five times and incubated with goat anti-human IgG (Fc-specific) peroxidase conjugate  
240 (1:5000; IgG-HRP, Sigma), or goat anti-human IgA ( $\alpha$ -chain specific), F(ab')<sub>2</sub> fragment  
241 peroxidase conjugate (1:5000; IgA-HRP, Sigma) or goat anti-human IgM peroxidase conjugate  
242 (1:2000; IgM-HRP, Southern Biotech) for 1 h at room temperature. The plate was then  
243 developed using 100  $\mu$ l O-phenylenediamine dihydrochloride (OPD; Sigma) for 12 min before  
244 the reaction was stopped with 50  $\mu$ l 3M hydrochloric acid (HCl, Sigma). The plates were read  
245 at 490 nm using a Versamax microplate reader (Molecular Devices) using SoftMax Pro  
246 software (version 5.3). A cutoff for positivity was set at two standard deviations (SD) above  
247 the mean optical density (OD) of pre-pandemic samples. For determining endpoint titers, 2-  
248 fold serial dilutions were performed for 20 PCR+ samples and 40 pre-pandemic controls. Area  
249 under the curve (AUC) was determined and the positivity threshold was calculated as before,  
250 mean+2SD. All patient samples were also analysed using the anti-SARS-CoV-2 ELISA (IgG;  
251 Euroimmun), which uses the S1 domain of the spike protein, according to the manufacturer's  
252 instructions.

253

### 254 **Statistical analysis**

255 Statistical analyses were performed in Prism (GraphPad, version 8). Nonparametric tests were  
256 used for all comparisons. The Friedman test with Dunn's multiple comparison test was used  
257 for matched comparisons; the Mann–Whitney U unmatched and Wilcoxon matched pairs t-  
258 tests were used for unmatched and paired samples, respectively. Spearman Rank tests were  
259 used for all correlations. AUC was calculated in Prism. A p value of <0.05 was considered  
260 statistically significant.

261

## 262 **Results**

### 263 **SARS-CoV-2 antigen expression in plants**

264 The S1 and RBD portions of the Spike protein of SARS-CoV-2 were expressed in *Nicotiana*  
265 *benthamiana* as fusions to the rabbit IgG Fc tag. Western blot and SDS-PAGE analysis  
266 revealed expression of purified S1 (**Figure 1A & B**) and RBD (**Figure 1C & D**) at the expected  
267 protein sizes of ~140kDa and ~100kDa, respectively. Higher molecular weight bands of  
268 ~280kDa and ~200kDa indicated possible dimer formation of S1 and RBD, respectively. In  
269 addition, lower molecular weight bands indicated potentially multiple cleavage products of S1  
270 and RBD in the preparations.

271

### 272 **Participant description**

273 Serum samples were collected from 77 volunteers who had previously tested positive for  
274 SARS-CoV-2 by PCR. The demographic and clinical characteristics of the participants are  
275 summarized in **Table 1**. Just over half the participants were female, and the median age was  
276 39 years. The date of onset of symptoms was not available, but samples were taken a median  
277 of 6 weeks after SARS-CoV-2 PCR positivity. The majority of patients (79%) experienced  
278 mild or moderate COVID-19 disease. We also included 58 archived plasma samples from HIV-  
279 infected and uninfected individuals collected prior to the pandemic (2011-2012) as negative  
280 controls for our assay.

281

### 282 **Plant-produced S1 and RBD proteins are suitable for ELISA detection of SARS-CoV-2** 283 **antibodies**

284 In order to test whether plant-produced SARS-CoV-2 antigens were able to detect virus-  
285 specific antibodies from infected patients, we screened convalescent sera from 77 volunteers  
286 who had recovered from COVID-19. Individuals were tested for reactivity against both S1 and  
287 RBD antigens by a standard indirect ELISA based on a published protocol (Stadlbauer et al.,  
288 2020). Archived pre-pandemic plasma samples from 58 individuals, including 27 HIV-infected  
289 persons, were used to test the background reactivity to SARS-CoV-2 S1 and RBD. The  
290 threshold for positivity was set at two standard deviations above the mean optical density (OD)  
291 of the pre-pandemic samples.

292 Of the 77 COVID-19 convalescent serum samples, 51 (66%) tested positive for SARS-  
293 CoV-2-specific IgG against S1, and 48 (62%) tested positive against RBD (**Figure 2A & B**).  
294 In contrast, only 1/58 pre-pandemic plasma samples showed reactivity above the positivity  
295 cutoff. As expected, S1 and RBD IgG OD values correlated strongly ( $r=0.977$ ;  $p<0.0001$ ; data  
296 not shown). In order to independently validate our results, the same sera were run in a separate  
297 laboratory in a blinded manner, using a commercial IgG ELISA based on S1 antigen from  
298 Euroimmun. All samples that were positive by the commercial ELISA test for SARS-CoV-2  
299 S1 antibodies were positive in our assay (42/77). We detected nine additional samples that were  
300 positive in our assay, two of which had high OD values well above our threshold for positivity,  
301 and six that were also positive for RBD-specific IgG. We demonstrated a strong and significant  
302 direct correlation for sample OD values between the two assays ( $r=0.89$ ,  $p<0.0001$ ; **Figure**



303 **2C)**. Of note, we found no association between SARS-CoV-2-specific IgG OD values and  
304 disease severity or days post PCR positivity (data not shown).

305 Thus, our ELISA using plant-produced recombinant viral proteins performed similarly  
306 to a highly sensitive and specific commercial SARS-CoV-2 ELISA.

307

### 308 **Determination of immunoglobulin titers and isotypes**

309 We next determined the titers of SARS-CoV-2-specific IgG, IgM and IgA responses in a subset  
310 of 20 SARS-CoV-2 convalescent serum samples and 40 pre-pandemic samples. Assays were  
311 performed on serially diluted samples (**Figure 3A-F**) to determine endpoint titers and AUC  
312 values for quantitative interrogation of the data (**Figure 3G-L**). S1-specific IgG was detected  
313 in sera of 15/20 individuals (75%), IgM in 13/20 (65%) and IgA in 12/20 (70%) of individuals  
314 (**Figure 3G-I**). The median AUCs of IgG, IgM and IgA were significantly higher in  
315 convalescent individuals compared to pre-pandemic ( $p < 0.0001$  for all). Results for RBD-  
316 specific IgG were similar (**Figure 3J-L**). Interestingly, of the five SARS-CoV-2 convalescent  
317 sera that tested S1 IgG negative, three had S1-specific IgM and one had S1-specific IgA.  
318 Similarly, of the four samples negative for RBD-specific IgG three were positive for IgM and  
319 one was double positive for IgM and IgA. Therefore, SARS-CoV-2 S1-specific antibodies were  
320 detected in 19/20 convalescent samples and RBD-specific antibodies in 20/20 samples.

321 Further examination of S1-specific antibody isotypes revealed that approximately one  
322 third of individuals were positive for IgG, IgM and IgA ( $n=7/19$ ), a smaller proportion has both  
323 IgG and IgM or IgG and IgA ( $n=3$  and  $4$ , respectively), while some individuals were positive  
324 for only IgG ( $n=1$ ), IgM ( $n=3$ ) or IgA ( $n=1$ ) (**Figure 4A**). RBD-specific isotypes gave similar  
325 results (**Figure 4B**). There was a significant correlation between S1-specific IgG and IgM  
326 ( $r=0.595$ ,  $p < 0.007$ ; **Figure 4C**) and anti-RBD ( $r=0.045$ ,  $p < 0.045$ ; data not shown). S1-specific  
327 IgG showed a trend towards a correlation with IgA ( $r=0.423$ ,  $p=0.07$ ; **Figure 4D**), whilst RBD-  
328 specific IgG correlated significantly with IgA ( $r=0.635$ ,  $p < 0.003$ ; data not shown). There was  
329 no correlation between IgM and IgA responses for either S1 or RBD (data not shown).

330 Endpoint titers for S1- and RBD-specific IgG, IgM and IgA were determined. S1-  
331 specific IgG endpoint titers in 33% of the samples were high (20% at 1:1600 and 13% at 1:800),  
332 13% were moderate (1:400) and the majority (54%) of samples had low titers (27% at 1:50,  
333 20% at 1:100 and 7% at 1:200) (**Figure 4E**). S1-specific IgA titers were lower than IgG and  
334 only 2 individuals have a titer of 1:800 or 1:400 each, and the remaining 84% had low titers  
335 ( $= < 1:200$ ; **Figure 4F**). IgM titers for both S1 and RBD were all low ( $= < 1:100$ ; data not  
336 shown). RBD-specific titers for IgG and IgM were similar to those S1, with the exception of  
337 two donors who had titers of 1:3200 (data not shown).

338

### 339 **Detection of SARS-CoV-2-specific antibodies in saliva**

340 Given that virus-specific serum antibodies were readily detectable using plant-produced  
341 SARS-CoV-2 antigens, we investigated the detection of salivary IgG and IgA using our assay.  
342 We compared antibody responses to SARS-CoV-2 antigens in paired saliva and serum from  
343 10 participants. In these preliminary analyses, 1/7 samples that had detectable S1-specific  
344 serum IgG also demonstrated S1 IgG positivity in saliva (**Figure 5A**). Additionally, 2/5 IgA+

345 sera exhibited virus-specific IgA in saliva. An additional IgA+ sample was detected in saliva  
346 but absent from the serum (**Figure 5B**). This indicated that IgA was more readily detectable in  
347 saliva than IgG. Further analyses to determine robust thresholds for positivity of saliva  
348 immunoglobulins will be performed going forward. These preliminary results demonstrate the  
349 potential of our ELISA to detect antibodies to SARS-CoV-2 in saliva.

350

### 351 **Optimization of the ELISA assay**

352 The in-house ELISA diagnostic assay in this study was developed from the published protocol  
353 (Stadlbauer et al., 2020). To determine whether we could further improve the robustness and  
354 sensitivity of the in-house ELISA assay, we optimized different parameters, including S1 and  
355 RBD antigen coating concentration as well as the coating and blocking buffers. Coating  
356 concentrations of 1, 2 and 4 µg/mL S1 and RBD were compared for SARS-CoV-2-specific IgG  
357 detection in four SARS-CoV-2 convalescent volunteers and three pre-pandemic samples. Two  
358 and 4 µg/ml demonstrated a significantly higher reactivity than 1 µg/ml for both S1 and RBD  
359 (**Figure 6A & B**;  $p=0.0005$  and  $p=0.004$ , respectively), with little increase in the background  
360 (negative control) signal. Coating of ELISA plates with antigen in different coating buffers,  
361 namely PBS and bicarbonate buffer, was also assessed (**Figure 6C**). No differences were  
362 detected, so PBS was selected for our procedure. A comparison of the blocking buffers PBS  
363 with 0.1% Tween-20 (PBS-T), PBS-T with 1% casein and PBS-T with 3% non-fat milk powder  
364 was performed (**Figure 6D**). PBS-T with 1% casein was selected based on background signal  
365 and positivity trends.

## 366 Discussion

367 There is a critical need for the development of serological tests to detect SARS-CoV-2  
368 antibodies. Population seroprevalence studies to estimate the extent of pandemic spread in  
369 communities, and studies defining protective immunity to SARS-CoV-2, all depend on reliable  
370 serological tests. In addition, serological assays are required for the development and  
371 evaluation of an effective vaccine. Ideally, such tests need to be cost-effective and easy to scale  
372 up to be beneficial in low-income settings. In this study, we describe the establishment of an  
373 indirect SARS-CoV-2 antibody ELISA using the S1 and RBD antigens of the spike protein of  
374 SARS-CoV-2 expressed in *Nicotiana benthamiana*. S protein domains were selected because  
375 they are highly immunogenic and the primary target for neutralizing antibodies (Berry et al.,  
376 2010; Chen et al., 2020). Using sera from convalescent volunteers with a PCR-confirmed past  
377 SARS-CoV-2 infection, we detected SARS-CoV-2-specific IgG, IgA and IgM to viral S1 and  
378 RBD. Our results were highly concordant with a widely used, high sensitivity and specificity  
379 commercial S1 IgG ELISA kit (Euroimmun).

380 A range of expression systems exist for the generation of the recombinant proteins  
381 required for serological assays. Plant protein expression systems have some advantages over  
382 more widely-used mammalian or insect cell systems, as they do not require expensive media  
383 or growth conditions (Shanmugaraj et al., 2020). They are also advantageous over bacterial or  
384 yeast systems in that they may support post-translational modifications similar to that of  
385 mammalian cell lines, and lack contaminating pathogens or endotoxins that pose a problem  
386 when purifying desired proteins (Shanmugaraj et al., 2020; Maliga et al., 2004). Lack of correct  
387 protein glycosylation and recombinant protein yield are cited as disadvantages to using plants  
388 to express protein. However, *Nicotiana benthamiana* is favoured for protein expression due to  
389 its rapid generation of biomass, a defective post-transcriptional gene silencing system, and the  
390 extensive range of engineering strategies, including glycoengineering, that can be applied along  
391 its secretory pathway; all of which may overcome the challenge of low yield (Margolin et al.,  
392 2020). Thus, there is great potential to use plant-based expression systems for the rapid  
393 generation of serological assay reagents and even vaccines for pandemics, including the current  
394 global SARS-CoV-2 pandemic.

395 Using our ELISA with plant-derived recombinant viral proteins, we detected S1-  
396 specific IgG in 66.2% and RBD-specific IgG in 62.3% of individuals who had tested positive  
397 for SARS-CoV-2 by PCR in the past. Responses between the two protein fragments were  
398 highly correlated, as predicted, and the small difference in reactivity was not unexpected, given  
399 the greater number of epitopes in the larger S1 domain. Our sensitivity appears lower than that  
400 reported in the literature, with a seroprevalence of 90.1%-100% in individuals confirmed to  
401 have been SARS-CoV-2-infected by PCR (Amanat et al., 2020; Beavis et al., 2020; Long et  
402 al., 2020; Liu et al., 2020), and a lower seroprevalence (65.8%) in those who were diagnosed  
403 <14 days before serological testing (Pollán et al., 2020). However, we obtained highly  
404 concordant results between our assay and a validated commercial ELISA. In fact, the reported  
405 manufacturer's sensitivity of the Euroimmun S1-specific IgG ELISA is 94.4%. This suggests  
406 that the lack of S1-specific IgG detection from some recovered COVID-19 patients in our  
407 cohort is more likely due to low or absent IgG antibody at the time of sampling, rather than a  
408 lack of sensitivity in our assay. With regard to specificity, we detected IgG cross-reactivity to  
409 SARS-CoV-2 in 1/58 (1.7%) of pre-pandemic plasma samples from a cohort of HIV-infected  
410 and uninfected volunteers with latent TB infection, giving a specificity of 98.3%. Cross-  
411 reactive antibody responses, while lower in magnitude, have been reported in SARS-CoV-2  
412 unexposed individuals (Khan et al., 2020), and likely result from past infections with common

413 circulating hCoVs. Thus, our assay for SARS-CoV-2-specific IgG performs as well as a widely  
414 used commercial kit in terms of sensitivity and specificity, and is suitable for serological studies  
415 of humoral responses in the current pandemic.

416 Several factors may affect antibody detection after SARS-CoV-2 exposure. Timing of  
417 sampling is important, with IgM typically arising first, peaking two to three weeks after  
418 symptom onset (Long et al., 2020). IgG is typically detected after IgM in serum, peaking at  
419 roughly the same time (Huang et al., 2020). However, in SARS-CoV-2 infection, antibodies  
420 may not follow this typical pattern of seroconversion (Long et al., 2020; Seow et al., 2020) and  
421 seroconversion to a single Ig subclass has been described (Seow et al., 2020). Interestingly,  
422 when investigating isotype responses in addition to IgG, we showed that a further 4/20 (20%)  
423 donors had S1-specific IgA or IgM. Thus, in our initial screen where 34% of individuals who  
424 had previously tested positive for SARS-CoV-2 by PCR had no detectable IgG responses, 20%  
425 may have had isotype responses other than IgG. A recent study showed that combined detection  
426 of IgG, IgM and IgA increased the overall detection of SARS-CoV-2 antibodies, enabling  
427 better identification of infected individuals with low antibody levels (Faustini et al., 2020).

428 A further factor in detection of antibodies to SARS-CoV-2 is waning of the response  
429 over time, which has potentially important consequences for the duration of protective  
430 immunity and the risk of reinfection. One study showed a decrease in IgG in half of patients  
431 tested, calculating an overall half-life of 36 days for IgG (Ibarrondo et al., 2020). Waning of  
432 binding antibody responses to S and RBD has been reported soon after their peak, particularly  
433 IgM and IgA antibodies, but IgG responses have shown persistence for greater than 90 days  
434 post-illness onset (Seow et al., 2020; Wajnberg et al., 2020). A limitation of our study was that  
435 we did not have information on the date of COVID-19 symptom onset in our cohort, limiting  
436 our analyses to time post PCR positivity, which did not yield a relationship with antibody  
437 positivity or OD value. Additional factors that may also influence antibody generation and  
438 kinetics include disease severity, age and comorbidities. We found no relationship between  
439 increasing disease severity and antibody positivity or OD value, likely due to the fact that the  
440 majority of our study participants had mild to moderate COVID-19.

441 We determined endpoint titers of binding antibodies to S1 and RBD in a subset of 20  
442 convalescent participants in our cohort. Several studies have demonstrated that binding  
443 antibody titers against S correlate with neutralization capacity (Amanat et al., 2020; Okba et  
444 al., 2020; Premkumar et al., 2020). A recent study reporting S-specific IgG titers in almost 20  
445 000 patients screened for eligibility as convalescent plasma donors demonstrated that 70% of  
446 IgG+ donors had high titers (>1:960) of antibodies (Wajnberg et al., 2020). Importantly, 100%  
447 of those with titers >2880 exhibited neutralizing activity (ID<sub>50</sub> of >1:10). Although we  
448 performed our study on a much smaller sample size, we detected titers of S1 or RBD-specific  
449 IgG of up to 1:3200. However, the majority of donors (54%) had titers below 1:200, and only  
450 a third of samples had high titers >1:800. Unsurprisingly, IgA and IgM titers were lower than  
451 IgG titers, and did not exceed 1:800 for IgA and 1:400 for IgM. Further studies characterising  
452 antibody titers in recovered COVID-19 patients in our setting are warranted.

453 Saliva is a non-invasive specimen that can be self-collected and thus represents an  
454 attractive sample type for large-scale sampling such as in seroprevalence studies. We  
455 demonstrate that our ELISA can detect SARS-CoV-2-specific IgG and IgA not only in serum,  
456 but also in saliva. Further optimization and validation will be required to establish the  
457 conditions for optimal detection of antibodies in saliva, including the use of pre-pandemic  
458 saliva samples. Recent studies have reported the detection of S-specific antibodies in saliva  
459 (Faustini et al., 2020; Randad et al., 2020). Faustini et al. (2020) suggested that the use of both

460 serum and saliva samples increased the detection of SARS-CoV-2 antibody responses,  
461 reporting substantial discordance between the two sample types. Although preliminary, our  
462 results provide the basis for investigating the detection of SARS-CoV-2 antibodies in saliva  
463 using antigens expressed in plants.

464 In conclusion, our study demonstrates that recombinant SARS-CoV-2 proteins  
465 produced in plants enable the robust detection of SARS-CoV-2-specific antibodies. One of our  
466 aims was to develop a cost-effective serological assay for both large-scale seroepidemiology  
467 as well as research studies of SARS-CoV-2 humoral immunity. We achieved this by making  
468 use of plants for the production of viral antigens, which has the benefit of rapid scale-up, and  
469 sourcing reagents that were available locally and thus available at a lower cost. Our ELISA can  
470 be used to evaluate SARS-CoV-2 seroprevalence and describe the kinetics of the humoral  
471 immune response in infected individuals. Serological studies in a setting like ours, in South  
472 Africa, where comorbidities such as HIV and TB are highly prevalent, are underexplored and  
473 can benefit from this assay.



## 474 **References**

- 475 Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M.,  
476 et al. (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat.*  
477 *Med.* 26, 1033–1036. doi:10.1038/s41591-020-0913-5.
- 478 Beavis, K. G., Matushek, S. M., Abeleda, A. P. F., Bethel, C., Hunt, C., Gillen, S., et al. (2020).  
479 Evaluation of the EUROIMMUN anti-SARS-CoV-2 ELISA assay for detection of IgA  
480 and IgG antibodies. *J. Clin. Virol.* 129, 104468. doi:10.1016/j.jcv.2020.104468.
- 481 Berry, J. D., Hay, K., Rini, J. M., Yu, M., Wang, L., Plummer, F. A., et al. (2010). Neutralizing  
482 epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure  
483 or mAb technology. *MAbs* 2 (1), 53–66. doi:10.4161/mabs.2.1.10788.
- 484 Chan, J. F. W., Yuan, S., Kok, K. H., To, K. K. W., Chu, H., Yang, J., et al. (2020). A familial  
485 cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-  
486 person transmission: a study of a family cluster. *Lancet* 395(10223), 514-523.  
487 doi:10.1016/S0140-6736(20)30154-9.
- 488 Chen, W. H., Hotez, P. J., and Bottazzi, M. E. (2020). Potential for developing a SARS-CoV  
489 receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine  
490 against coronavirus infectious disease (COVID)-19. *Hum. Vaccines Immunother.* 16 (6),  
491 1239-1242. doi:10.1080/21645515.2020.1740560.
- 492 Faustini, S. E., Jossi, S. E., Perez-Toledo, M., Shields, A., Allen, J. D., Watanabe, Y., et al.  
493 (2020). Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum  
494 and saliva enhances detection of infection. *medRxiv* 2020.06.16.20133025.  
495 doi:10.1101/2020.06.16.20133025.
- 496 Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan,  
497 S. M., et al. (2020). A systematic review of antibody mediated immunity to  
498 coronaviruses: antibody kinetics, correlates of protection, and association of antibody  
499 responses with severity of disease. *medRxiv* 2020.04.14.20065771.  
500 doi:10.1101/2020.04.14.20065771.
- 501 Ibarrondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A.,  
502 et al. (2020). Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-  
503 19. *N. Engl. J. Med.*, NEJMc2025179. doi:10.1056/NEJMc2025179.
- 504 Kapila, J., De Rycke, R., Van Montagu, M., and Angenon, G. (1997). An Agrobacterium-  
505 mediated transient gene expression system for intact leaves. *Plant Sci.* 122(1), 101-108.  
506 doi:10.1016/S0168-9452(96)04541-4.
- 507 Khan, S., Nakajima, R., Jain, A., Assis, R. R. de, Jasinskas, A., Obiero, J. M., et al. (2020).  
508 Analysis of serologic cross-reactivity between common human coronaviruses and SARS-  
509 CoV-2 using coronavirus antigen microarray. *bioRxiv* 2020.03.24.006544.  
510 doi:10.1101/2020.03.24.006544.
- 511 Letko, M., Marzi, A., and Munster, V. (2020). Functional assessment of cell entry and receptor  
512 usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat. Microbiol.* 5(4),  
513 562-569. doi:10.1038/s41564-020-0688-y.

- 514 Li, F. (2016). Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu. Rev.*  
515 *Viol.* 3 (1), 237–261. doi:/10.1146/annurev-virology-110615-042301.
- 516 Liu, W., Liu, L., Kou, G., Zheng, Y., Ding, Y., Ni, W., et al. (2020). Evaluation of nucleocapsid  
517 and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies  
518 against SARS-CoV-2. *J. Clin. Microbiol.* 58(6), e00461-20. doi:/10.1128/JCM.00461-  
519 20.
- 520 Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y., et al. (2020a). Antibody  
521 responses to SARS-CoV-2 in patients with COVID-19. *Nat. Med.* 26(6), 845–848.  
522 doi:10.1038/s41591-020-0897-1.
- 523 Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., et al. (2020). Genomic characterisation and  
524 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor  
525 binding. *Lancet* 395(10224), 565-574. doi:/10.1016/S0140-6736(20)30251-8.
- 526 Maclean, J., Koekemoer, M., Olivier, A. J., Stewart, D., Hitzeroth, I. I., Rademacher, T., et al.  
527 (2007). Optimization of human papillomavirus type 16 (HPV-16) L1 expression in  
528 plants: Comparison of the suitability of different HPV-16 L1 gene variants and different  
529 cell-compartment localization. *J. Gen. Virol.* 88(5), 1460-1469. doi:10.1099/vir.0.82718-  
530 0.
- 531 Maliga, P., and Graham, I. (2004). Plant biotechnology: Molecular farming and metabolic  
532 engineering promise a new generation of high-tech crops. *Curr. Opin. Plant Biol.* 7(2),  
533 149-151. doi:/10.1016/j.pbi.2004.01.016.
- 534 Margolin, E. A., Strasser, R., Chapman, R., Williamson, A.-L., Rybicki, E. P., and Meyers, A.  
535 E. (2020). Engineering the plant secretory pathway for the production of next-generation  
536 pharmaceuticals. *Trends Biotechnol.* In press. doi:10.1016/j.tibtech.2020.03.004.
- 537 Neuman, B. W., Kiss, G., Kunding, A. H., Bhella, D., Baksh, M. F., Connelly, S., et al. (2011).  
538 A structural analysis of M protein in coronavirus assembly and morphology. *J. Struct.*  
539 *Biol.* 174(1), 11-22. doi:/10.1016/j.jsb.2010.11.021.
- 540 Okba, N., Muller, M., Li, W., Wang, C., GeurtsvanKessel, C., Corman, V., et al. (2020). SARS-  
541 CoV-2 specific antibody responses in COVID-19 patients. *medRxiv*  
542 2020.03.18.20038059. doi:/10.1101/2020.03.18.20038059.
- 543 Pogrebnyak, N., Golovkin, M., Andrianov, V., Spitsin, S., Smirnov, Y., Egolf, R., et al. (2005).  
544 Severe acute respiratory syndrome (SARS) S protein production in plants: Development  
545 of recombinant vaccine. *Proc. Natl. Acad. Sci. U.S.A.* 102(25), 9062-906.  
546 doi:/10.1073/pnas.0503760102.
- 547 Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M.,  
548 et al. (2020). Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,  
549 population-based seroepidemiological study. *Lancet* 6736 (20), 1–11.  
550 doi:10.1016/S0140-6736(20)31483-5.
- 551 Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A., et  
552 al. (2020). The receptor binding domain of the viral spike protein is an immunodominant

- 553 and highly specific target of antibodies in SARS-CoV-2 patients. *Sci. Immunol.* 5(48),  
554 eabc8413. doi:10.1126/sciimmunol.abc8413.
- 555 Randad, P. R., Pisanic, N., Kruczynski, K., Manabe, Y. C., Thomas, D., Pekosz, A., et al.  
556 (2020). COVID-19 serology at population scale: SARS-CoV-2-specific antibody  
557 responses in saliva. *medRxiv* 2020.05.24.20112300. doi:/10.1101/2020.05.24.20112300.
- 558 Remy, M. M., Alfter, M., Chiem, M. N., Barbani, M. T., Engler, O. B., and Suter-Riniker, F.  
559 (2019). Effective chemical virus inactivation of patient serum compatible with accurate  
560 serodiagnosis of infections. *Clin. Microbiol. Infect.* 25(7), 907-e7.  
561 doi:10.1016/j.cmi.2018.10.016.
- 562 Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W., et al. (2020). Isolation of  
563 potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small  
564 animal model. *Science* eabc7520. doi:/10.1126/science.abc7520.
- 565 Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K. J. A., Hemmings, O., et al. (2020).  
566 Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection.  
567 *medRxiv* 2020.07.09.20148429. doi:10.1101/2020.07.09.20148429.
- 568 Shanmugaraj, B., Malla, A., and Phoolcharoen, W. (2020). Emergence of novel coronavirus  
569 2019-nCoV: Need for rapid vaccine and biologics development. *Pathogens* 9(2), 148.  
570 doi:10.3390/pathogens9020148.
- 571 Shanmugaraj, B., and Ramalingam, S. (2014). Plant expression platform for the production of  
572 recombinant pharmaceutical proteins. *Austin J Biotechnol Bioeng* 1(6), 4. Available at:  
573 [https://austinpublishinggroup.com/biotechnology-bioengineering/fulltext/ajbtbe-v1-](https://austinpublishinggroup.com/biotechnology-bioengineering/fulltext/ajbtbe-v1-id1026.php)  
574 [id1026.php](https://austinpublishinggroup.com/biotechnology-bioengineering/fulltext/ajbtbe-v1-id1026.php).
- 575 Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., et  
576 al. (2020). SARS-CoV-2 seroconversion in humans: A detailed protocol for a serological  
577 assay, antigen production, and test setup. *Curr. Protoc. Microbiol.* 57(1), e100.  
578 doi:10.1002/cpmc.100.
- 579 Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C. K., Zhou, J., et al. (2016). Epidemiology, genetic  
580 recombination, and pathogenesis of coronaviruses. *Trends Microbiol.* 24(6), 490-502.  
581 doi:10.1016/j.tim.2016.03.003.
- 582 Tan, W., Zhao, X., Ma, X., Wang, W., Niu, P., Xu, W., et al. (2020). A novel coronavirus  
583 genome identified in a cluster of pneumonia cases - Wuhan, China 2019–2020. *China*  
584 *CDC Wkly.* 2(4), 61-62. doi:/10.46234/ccdcw2020.017.
- 585 Tortorici, M. A., and Veessler, D. (2019). “Structural insights into coronavirus entry,” in  
586 *Advances in Virus Research* (Academic Press Inc.) 105, 93–116.  
587 doi:10.1016/bs.aivir.2019.08.002.
- 588 Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., et al. (2020).  
589 SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable  
590 for at least three months. *medRxiv* 2020.07.14.20151126.  
591 doi:10.1101/2020.07.14.20151126.

- 592 Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., and Veerler, D. (2020).  
593 Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 180(2),  
594 281–292. doi:/10.1016/j.cell.2020.02.058.
- 595 Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., et al. (2020).  
596 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*  
597 367(6483), 1260-1263. doi:/10.1126/science.abb2507.
- 598 Yamamoto, T., Hoshikawa, K., Ezura, K., Okazawa, R., Fujita, S., Takaoka, M., et al. (2018).  
599 Improvement of the transient expression system for production of recombinant proteins  
600 in plants. *Sci. Rep.* 8(1), 1-10. doi:/10.1038/s41598-018-23024-y.
- 601 Yin, J., Li, G., Ren, X., and Herrler, G. (2007). Select what you need: A comparative evaluation  
602 of the advantages and limitations of frequently used expression systems for foreign  
603 genes. *J. Biotechnol.* 127(3), 335-347. doi:/10.1016/j.jbiotec.2006.07.012.
- 604 Zhao, R., Li, M., Song, H., Chen, J., Ren, W., Feng, Y., et al. (2020). Early detection of SARS-  
605 CoV-2 antibodies in COVID-19 patients as a serologic marker of infection. *Clin. Infect.*  
606 *Dis.* ciaa523. doi:/10.1093/cid/ciaa523.
- 607 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A novel coronavirus  
608 from patients with pneumonia in China, 2019. *N. Engl. J. Med.* 382(8), 727–733.  
609 doi:/10.1056/NEJMoa2001017.

610 **Table**

611

612 **Table 1: Characteristics of COVID-19 patients (n=77)**

613

---

Sex female, n (%)	42 (55)
Age (years) <sup>a</sup>	39 [29-50]
Time since positive PCR test (days) <sup>a</sup>	42 [29-52]
Disease severity, n (%) <sup>b</sup>	
<i>Asymptomatic</i>	5 (7)
<i>Mild</i>	23 (30)
<i>Moderate</i>	38 (49)
<i>Severe</i>	2 (3)

---

<sup>a</sup> median and interquartile range

<sup>b</sup> not available for n=9 participants

614

615



616 **Figure legends**

617 **Figure 1. Analysis of plant-expressed SARS-CoV-2 spike antigens after Protein A**  
618 **purification.** (A) Coomassie-stained SDS-PAGE gel and (B) Western blot of S1-rabbit Fc  
619 fusion protein (2 µg of concentrated elution fraction). Lines on the left indicate molecular  
620 weight marker (Spectra Multicolor Broad range protein ladder) in kDa. The arrow indicates the  
621 expected size for recombinant S1 protein (~140 kDa). (C) Coomassie-stained SDS-PAGE gel  
622 and (D) Western blot of RBD-rabbit Fc fusion protein (5 µg of concentrated elution fraction).  
623 Arrows indicate expected size for RBD-rabbit Fc conjugate (~100 kDa).

624

625 **Figure 2. Detection of IgG using plant-expressed SARS-CoV-2 spike antigens in COVID-**  
626 **19 convalescent volunteers and pre-pandemic controls using an in-house ELISA.**  
627 Reactivity to plant-expressed S1 (A) and RBD (B) in pre-pandemic samples from HIV-  
628 uninfected individuals (n=31), HIV-infected individuals (n=27), and SARS-CoV-2 PCR  
629 positive volunteers (n=77). Dotted lines indicate threshold for positivity, calculated as the mean  
630 optical density (OD) + 2SD of the pre-pandemic samples. (C) Correlation of the OD values for  
631 S1-specific IgG in our in-house ELISA and the commercial Euroimmun IgG S1 ELISA kit.  
632 Statistical analyses were performed using a non-parametric Spearman rank correlation. Each  
633 dot represents one individual.

634

635 **Figure 3. Semi-quantitative detection of S1- and RBD-specific IgG, IgM and IgA.** Two-  
636 fold dilution series of sera for detection of S1-specific IgG (A), IgM (B), and IgA (C) and  
637 RBD-specific IgG (D), IgM (E) and IgA (F). COVID-19 convalescent volunteers (n=20) are  
638 indicated in red, and pre-pandemic controls (n=40) are indicated in black. (G-I) and (J-L), Data  
639 from the same experiment as in (A-C) and (D-F), respectively, but plotted as area under the  
640 curve (AUC). Horizontal lines represent median values. Dotted lines indicate the threshold for  
641 positivity. Statistical analyses were performed using a Mann-Whitney U test. A p value of  
642 <0.05 was considered statistically significant.

643

644 **Figure 4. The relationship between IgG, IgM and IgA responses to S1 and RBD SARS-**  
645 **CoV-2 antigens.** (A) Proportions of COVID-19 convalescent volunteers mounting different  
646 combinations of IgG, IgM and IgA specific for S1 (A) (n=19), and RBD (B) (n=20).  
647 Relationship between S1-specific IgG and IgM (C) and IgG and IgA (D). Statistical analyses  
648 were performed using a non-parametric Spearman rank correlation. Proportion of convalescent  
649 volunteers with endpoint titers for IgG (E) and IgA (F) of 1:50, 1:100, 1:200, 1:400, 1:800,  
650 1:1600.

651


652 **Figure 5. Detection of S1-specific antibodies in saliva.** Comparison of paired serum and  
653 saliva S1-specific IgG (A) and IgA (B) (n=10). Dotted lines indicate the positivity threshold  
654 for serum.

655

656 **Figure 6. Optimization of ELISA antigen coating concentration, coating buffer and**  
657 **blocking buffer.** The effect of antigen coating concentration (1, 2 and 4  $\mu\text{g/ml}$ ) was tested for  
658 (A) S1 and (B) RBD, using serum samples from SARS-CoV-2 positive convalescent  
659 participants (n=7). Statistical analyses were performed using the Friedman test with Dunn's  
660 test for multiple comparisons. (C) Comparison of phosphate buffered saline (PBS) and  
661 bicarbonate buffer for coating viral antigens. Statistical analyses were performed using a  
662 Wilcoxon matched pair's test. (D) The effect of different blocking solutions. Statistical analysis  
663 was performed using the Friedman test with Dunn's test for multiple comparisons.

664

**FIGURE 1**




665

666

667


668

**FIGURE 2**



669

**FIGURE 3**




670

671




**FIGURE 4**



672


673

**FIGURE 5**



674

**FIGURE 6**



675